Aptamer  has published news detailing strong technical progress across a number of its ongoing strategic projects with global consumer goods and pharmaceutical partners. Each continue to produce positive results, providing increased validation and progression towards commercial products with potential to deliver value inflection points for the Group across diverse applications. Today’s news covers Aptamer’s partnership with Unilever, its development of an Alzheimer’s disease diagnostic test with Neuro-Bio and ongoing collaboration with AstraZeneca, while also continuing to progress novel binder development in different areas for a number of other major life-science players. Based simply on being able to sustain its existing trajectory of incoming Fee-For-Service (‘FFS’) work while completing the scale back of its cost base, the Board projects cash-in hand (incl. annual R&D tax credits) will be sufficient to satisfy its working capital needs out to end-June 2026, by which time anticipated collection of milestone payments, licensing fees and/or royalties offer potential for it to become financially self-sustaining going forward. Even if initial passive income receipts, which could commence during the current financial period, may be relatively modest the potential is there to multiply substantially thereafter. Seemingly unrecognised in the Group’s current valuation, any such breakthrough adoption(s) would be transformative for Aptamer, both financially and in terms of reputation.